SEC Filing Summary for Immix Biopharma, Inc.

Magda Marquet, a director at Immix Biopharma, Inc., was granted 6,250 restricted stock units (RSUs) on May 22, 2026. These RSUs are set to vest in full on the earlier of the one-year anniversary of the grant date or the date of the Issuer's 2027 annual meeting of stockholders, provided she continues her service. Additionally, Marquet was granted a stock option to purchase 12,500 shares of common stock at an exercise price of $8.78 per share, with an expiration date of May 22, 2036. This option will vest over 12 months, with any remaining unvested portion vesting on the date of the 2027 Annual Meeting if it occurs before the first anniversary of the grant date. Marquet is also associated with Alma Life Sciences, LLC, and may be deemed to beneficially own securities held by the LLC, though she disclaims beneficial ownership except to the extent of her pecuniary interest. Following these transactions, Marquet directly owns 52,342 shares of common stock, and indirectly owns 20,000 shares through Alma Life Sciences, LLC. She also holds 12,500 shares through the stock option.